2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2981

Prospective Cohort of Surgically-Diagnosed Aortitis at the Ottawa Hospital
Abstract Number: 645

Prospective Observational Real-Life Study (STRATEGE) Shows the Efficacy of Treat-to-Target Strategy and Methotrexate Monotherapy Optimization in Patients with Established Rheumatoid Arthritis
Abstract Number: 2797

Prospective Validation of a Panel of Autoantibodies in Combination with C4d-Bound Complement Activation Products for the Differential Diagnosis of Systemic Lupus Erythematosus
Abstract Number: 636

Prospective, Intervention, Multicenter Study of Utility of Biologic Drug Monitoring with Respect to the Efficacy and Cost of Adalimumab Tapering in Patients with Rheumatic Diseases (34-week descriptive data)
Abstract Number: 2053

Prosthetic Joint Infection with Staphylococcus Aureus: Recurrence after Surgical Treatment in U.S. Veterans with and without Rheumatoid Arthritis
Abstract Number: 3132

Protective Effects of Replacing Sedentary Time with Light and Moderate to Vigorous Physical Activity on Functional Limitation in Knee OA
Abstract Number: 183

Protective Role of Mucosal-Associated Invariant T (MAIT) Cells in an Imiquimod-Induced Psoriasis Model
Abstract Number: 1108

Protein Citrullinations By PAD Enzymes Promote Dendritic Cell Transdifferentiation into Osteoclast and Generate Targets for RA-Specific Antibodies
Abstract Number: 1664

Protein Fingerprinting Screening Specific Proteins in Serum of Patients with Ankylosing Spondylitis
Abstract Number: 174

Protein Modified with Citrulline and/or Malondialdehyde-Acetaldehyde Bind to Different Scavenger Receptors
Abstract Number: 2269

Proteinaceous Amorphous Calcium Carbonates As a Novel Family of Crystals in Synovial Fluid from Symptomatic Joints
Abstract Number: 2037

Proteostasis Dysregulation and Autoinflammation in Patients with TRNT1 Deficiency
Abstract Number: 2770

Psoriatic Arthritis Limits Patients’ Abilities to Undertake Activities Crucial for Normal Daily Life and Impacts Happiness, Results from a Multinational Real-World Sample
Abstract Number: 2978

Psychiatric Involvement and Behcet’S Syndrome: Does Bipolar Disorder Represent a Clinical Feature of the Disease?
Abstract Number: 1804

Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: a Single Centre Experience

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].